Compare POWWP & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POWWP | SCLXW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 81 | 34 |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | POWWP | SCLXW |
|---|---|---|
| Price | $23.75 | $0.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.0K | ★ 3.4K |
| Earning Date | N/A | 03-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,152,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.02 |
| 52 Week Low | $22.02 | $0.05 |
| 52 Week High | $25.50 | $0.64 |
| Indicator | POWWP | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 38.83 | 53.30 |
| Support Level | $23.71 | $0.11 |
| Resistance Level | $24.53 | $0.18 |
| Average True Range (ATR) | 0.25 | 0.02 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 24.00 | 76.94 |
Outdoor Holding Co Formerly AMMO Inc is the owner of GunBroker.com, the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketing of ammunition and ammunition component products and the marketplace segment consists of the GunBroker.com marketplace. The company generates the majority of its revenue from the Ammunition segment.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.